BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28374164)

  • 1. Bilateral sciatic nerve neurolymphomatosis: PET/CT findings.
    Gorospe L; Gallego-Rivera JI; Rioja-Martín ME; Chinea-Rodríguez A
    Ann Hematol; 2017 Jun; 96(6):1059-1060. PubMed ID: 28374164
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neurolymphomatosis: diagnosis of extension and assessment of response to treatment with PET-CT].
    Durán C; Infante JR; Serrano J; Rayo JI; García L; Domínguez ML; Sánchez R
    Rev Esp Med Nucl; 2009; 28(6):295-8. PubMed ID: 19864049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve.
    Advani P; Paulus A; Murray P; Jiang L; Goff R; Pooley R; Jain M; Garner H; Foran J
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e117-20. PubMed ID: 25617034
    [No Abstract]   [Full Text] [Related]  

  • 4. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
    Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
    Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
    Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
    Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
    [No Abstract]   [Full Text] [Related]  

  • 7. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
    Swinnen LJ; Li H; Quon A; Gascoyne R; Hong F; Ranheim EA; Habermann TM; Kahl BS; Horning SJ; Advani RH
    Br J Haematol; 2015 Jul; 170(1):56-65. PubMed ID: 25823885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 10. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.
    Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-related lymphoma treated with maintenance thalidomide.
    Larson ML; Enschede SH; Gregory SA
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):231-4; discussion 234-5. PubMed ID: 16166993
    [No Abstract]   [Full Text] [Related]  

  • 14. Diffuse large B-cell lymphoma of the lung in a patient with nonspecific interstitial pneumonia.
    Gorospe Sarasúa L; Arrieta P; Chinea-Rodríguez A; de la Puente-Bujidos C
    Reumatol Clin (Engl Ed); 2019; 15(6):e151-e152. PubMed ID: 28867466
    [No Abstract]   [Full Text] [Related]  

  • 15. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.
    Vassilakopoulos TP; Pangalis GA; Chatziioannou S; Papageorgiou S; Angelopoulou MK; Galani Z; Kourti G; Prassopoulos V; Leonidopoulou T; Terpos E; Dimopoulou MN; Sachanas S; Kalpadakis C; Konstantinidou P; Boutsis D; Stefanoudaki E; Kyriazopoulou L; Siakantaris MP; Kyrtsonis MC; Variami E; Kotsianidis I; Symeonidis A; Michali E; Katodritou E; Kokkini G; Tsatalas C; Papadaki H; Dimopoulos MA; Sotiropoulos V; Pappa V; Karmiris T; Meletis J; Apostolidis J; Datseris I; Panayiotidis P; Konstantopoulos K; Roussou P; Rondogianni P
    Leukemia; 2016 Jan; 30(1):238-42. PubMed ID: 25971363
    [No Abstract]   [Full Text] [Related]  

  • 16. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
    Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of diffuse large B-cell lymphoma in the rituximab era].
    Kinoshita T
    Rinsho Ketsueki; 2009 Oct; 50(10):1342-50. PubMed ID: 19915341
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment strategy of gray zone lymphomas].
    Maruyama D
    Rinsho Ketsueki; 2014 Oct; 55(10):1912-9. PubMed ID: 25297755
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic utility of pre-transplantation [
    Mesguich C; Roch A; Hindié E; Milpied N; Bordenave L; Tlili G; Bouabdallah K
    Br J Haematol; 2020 Jan; 188(2):268-271. PubMed ID: 31388998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral hard palate masses.
    Schaberg SJ; Daniels CA; Loomer L; Addante RR
    J Oral Maxillofac Surg; 1993 Nov; 51(11):1262-7. PubMed ID: 7693900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.